EA202092814A1 - PYRIDONE DERIVATIVE, ITS COMPOSITION AND APPLICATION AS AN ANTIVIRAL DRUG - Google Patents

PYRIDONE DERIVATIVE, ITS COMPOSITION AND APPLICATION AS AN ANTIVIRAL DRUG

Info

Publication number
EA202092814A1
EA202092814A1 EA202092814A EA202092814A EA202092814A1 EA 202092814 A1 EA202092814 A1 EA 202092814A1 EA 202092814 A EA202092814 A EA 202092814A EA 202092814 A EA202092814 A EA 202092814A EA 202092814 A1 EA202092814 A1 EA 202092814A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
influenza
type
influenza virus
diseases
Prior art date
Application number
EA202092814A
Other languages
Russian (ru)
Inventor
Ли Чэнь
Цин Шао
Сяоцзянь Сюэ
Сяовэнь Ли
Original Assignee
Цзянси Цайши Фармасьютикал Текнолоджи Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Цзянси Цайши Фармасьютикал Текнолоджи Ко., Лтд. filed Critical Цзянси Цайши Фармасьютикал Текнолоджи Ко., Лтд.
Priority claimed from PCT/CN2019/071902 external-priority patent/WO2019141179A1/en
Publication of EA202092814A1 publication Critical patent/EA202092814A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к области медицинской химии и касается нового пиридонового производного, имеющего формулу (I), или его стереоизомера, фармацевтически приемлемой соли, сольвата или кристаллической формы и его применения в приготовлении лекарственного средства для предотвращения или лечения таких заболеваний, как вирусная инфекция гриппа типа A и/или вирусная инфекция гриппа типа B, в особенности его применения в качестве ингибитора кэп-зависимой эндонуклеазы субъединицы PA для предотвращения или лечения таких заболеваний, как вирусная инфекция гриппа типа A и/или вирусная инфекция гриппа типа B. Соединения по настоящему изобретению имеют значительную активность в ингибировании эндонуклеазы вируса гриппа и ДНК вируса гриппа, могут применяться в отдельности или в комбинации с ингибитором нейраминидазы, нуклеозидным лекарственным средством, PB2 ингибитором, PB1 ингибитором, M2 ингибитором или другими противогриппозными лекарственными средствами, значительно сокращают время инфекции гриппа, снижают смертность и имеют прекрасные перспективы клинического применения.The present invention relates to the field of medicinal chemistry and relates to a novel pyridone derivative having formula (I) or its stereoisomer, pharmaceutically acceptable salt, solvate or crystalline form and its use in the preparation of a medicament for the prevention or treatment of diseases such as influenza virus type A and / or influenza type B viral infection, especially its use as an inhibitor of the cap dependent PA subunit endonuclease for the prevention or treatment of diseases such as influenza type A viral infection and / or type B influenza virus infection. The compounds of the present invention have significant activity in inhibiting influenza virus endonuclease and influenza virus DNA, can be used alone or in combination with a neuraminidase inhibitor, nucleoside drug, PB2 inhibitor, PB1 inhibitor, M2 inhibitor or other anti-influenza drugs, significantly reduce the time influenza infections, reduce mortality and have excellent clinical potential.

EA202092814A 2018-12-12 2019-01-16 PYRIDONE DERIVATIVE, ITS COMPOSITION AND APPLICATION AS AN ANTIVIRAL DRUG EA202092814A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811517425.4A CN111303147A (en) 2018-12-12 2018-12-12 Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament
PCT/CN2019/071902 WO2019141179A1 (en) 2018-01-17 2019-01-16 Pyridone derivative, composition thereof and application thereof as anti-influenza drug

Publications (1)

Publication Number Publication Date
EA202092814A1 true EA202092814A1 (en) 2021-05-14

Family

ID=71148820

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092814A EA202092814A1 (en) 2018-12-12 2019-01-16 PYRIDONE DERIVATIVE, ITS COMPOSITION AND APPLICATION AS AN ANTIVIRAL DRUG

Country Status (2)

Country Link
CN (1) CN111303147A (en)
EA (1) EA202092814A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112898346B (en) * 2020-01-23 2023-11-10 南京知和医药科技有限公司 Water-soluble polycyclic compounds, pharmaceutical compositions and uses thereof
CN113683613B (en) * 2020-09-08 2023-06-09 知和(山东)大药厂有限公司 Polycyclic pyridine oxime compound, pharmaceutical composition and application thereof
CN114315827A (en) * 2020-12-28 2022-04-12 维眸生物科技（上海）有限公司 Polycyclic pyridopyridazine amide oxime-containing carbocyclic derivatives and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228653B (en) * 2010-09-24 2016-03-16 盐野义制药株式会社 The prodrug of the polycyclic carbamoylpyridone derivative be substituted
MX2021006404A (en) * 2015-04-28 2022-08-02 Shionogi & Co Substituted polycyclic pyridone derivative and prodrug thereof.
PE20181516A1 (en) * 2015-12-15 2018-09-21 Shionogi & Co MEDICATION TO TREAT FLU CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-FLU DRUG
KR20190014086A (en) * 2016-08-10 2019-02-11 시오노기세야쿠 가부시키가이샤 Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof
CN110041327B (en) * 2018-01-17 2022-01-21 江西彩石医药科技有限公司 Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament

Also Published As

Publication number Publication date
CN111303147A (en) 2020-06-19

Similar Documents

Publication Publication Date Title
PH12020551264A1 (en) Pyridone Derivative, Composition And Use As Antiviral Drug Thereof
MX2022010520A (en) Peptide macrocycles against acinetobacter baumannii.
HRP20230274T1 (en) Chemical compounds
EA201171376A1 (en) THYENO DERIVATIVES [2,3-B] PIRIDINE AS VIRUS REPLICATION INHIBITORS
BR112018001720A2 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as a histone deacetylase 6 inhibitor and the pharmaceutical composition comprising the same
MX368504B (en) Amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof.
MX2012007410A (en) Novel antiviral compounds.
HRP20210942T1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
HRP20211278T1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
BR112015021027A8 (en) therapeutic compounds, their uses, and pharmaceutical compositions
MX2013005478A (en) Antiviral condensed heterocyclic compounds.
EA202092814A1 (en) PYRIDONE DERIVATIVE, ITS COMPOSITION AND APPLICATION AS AN ANTIVIRAL DRUG
CU20170109A7 (en) DERIVATIVE OF QUINOLEINE TO TREAT AND PREVENT VIRAL INFECTIONS
HRP20202051T1 (en) Aryl substituted pyrimidines for use in influenza virus infection
SI2932970T1 (en) Antiviral therapy
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
BRPI0720220B8 (en) quinoline derivative, its pharmaceutical composition, its use, its preparation process, combination and product comprising it
MX2021004182A (en) Macrocyclic flu endonuclease inhibitors.
BRPI0719920B8 (en) quinoline derivative, its pharmaceutical composition, its use, its preparation process, combination and product comprising the same and intermediate compound
PH12020551340A1 (en) Methyllactam ring compound and pharmaceutical use thereof
MX2018009458A (en) Heterocyclic sulfonamide derivative and medicine containing same.
SG11201811516QA (en) Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof
EP4248960A3 (en) Novel triterpene derivatives as hiv inhibitors
EA202090844A2 (en) ANTI-VIRAL PHARMACEUTICAL COMPOSITION
WO2016016820A3 (en) Anionically modified n-sulfonic polyallylamine derivative, pharmaceutical composition comprising the n-sulfonic polyallylamine derivative as the active substance and use of said derivate for the production of a medicine